| Document Date: 2014-06-01 17:31:46
Open Document File Size: 136,86 KBShare Result on Facebook
City Cisplatin / Paris / / Country France / / Facility Julie Villa / Stable Disease / / IndustryTerm signal transduction network / / MedicalCondition non-squamous / non-small cell lung cancer / tumor / III disease / disease / NSCLC / concurrent cancer / Dyspnea / Progressive Disease / Nausea / traumatic subdural hematoma / Vomiting / Lung Cancer / radiation pneumonia / Gy (toxicity) Radiation Pneumonitis / Stable Disease / head and neck cancer / Radiation Pneumonitis / adenocarcinoma / unresectable non-small cell lung cancer / / MedicalTreatment radiation therapy / chemotherapy / radiotherapy / radiation / / Person Cecile Le Péchoux / Lidia Petit / Olivier Carré / Virginie Westeel / Delphine Lerouge / Alain Prevost / Franck Morin / Eric Pichon / Jean Trédaniel / Marie Paule Lebitasy / Lionel Moreau / Sylvie Friard / Francois Guichard / Gérard Zalcman / / Position RT / General / / Product cisplatin / / PublishedMedium DESIGN Week / / Technology radiation / Radiotherapy protocol / chemotherapy / / URL www.ifct.fr / /
SocialTag |
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.